Geode Capital Management LLC increased its position in Dynavax Technologies Corporation (NASDAQ:DVAX) by 6.6% during the first quarter, according to its most recent filing with the SEC. The fund owned 290,958 shares of the biopharmaceutical company’s stock after buying an additional 18,012 shares during the period. Geode Capital Management LLC owned about 0.66% of Dynavax Technologies Corporation worth $1,731,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in Dynavax Technologies Corporation by 14.4% in the first quarter. Vanguard Group Inc. now owns 1,825,662 shares of the biopharmaceutical company’s stock worth $10,864,000 after buying an additional 230,373 shares during the period. American International Group Inc. boosted its stake in Dynavax Technologies Corporation by 7.1% in the first quarter. American International Group Inc. now owns 23,934 shares of the biopharmaceutical company’s stock worth $142,000 after buying an additional 1,584 shares during the period. Blair William & Co. IL boosted its stake in Dynavax Technologies Corporation by 1.8% in the first quarter. Blair William & Co. IL now owns 1,346,494 shares of the biopharmaceutical company’s stock worth $6,059,000 after buying an additional 23,701 shares during the period. JPMorgan Chase & Co. boosted its stake in Dynavax Technologies Corporation by 600.6% in the first quarter. JPMorgan Chase & Co. now owns 113,595 shares of the biopharmaceutical company’s stock worth $675,000 after buying an additional 97,380 shares during the period. Finally, Quantitative Investment Management LLC bought a new stake in Dynavax Technologies Corporation during the first quarter worth approximately $1,404,000. 60.23% of the stock is currently owned by institutional investors.

Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) traded up 3.634% during midday trading on Thursday, reaching $17.825. 891,969 shares of the company’s stock were exchanged. The stock’s market cap is $975.87 million. Dynavax Technologies Corporation has a one year low of $3.20 and a one year high of $19.60. The firm has a 50 day moving average of $13.47 and a 200-day moving average of $8.01.

Dynavax Technologies Corporation (NASDAQ:DVAX) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.50) by $0.09. The company had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.15 million. Dynavax Technologies Corporation had a negative net margin of 1,323.99% and a negative return on equity of 92.09%. During the same period in the prior year, the business posted ($0.75) earnings per share. On average, equities research analysts anticipate that Dynavax Technologies Corporation will post ($1.58) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This report was first posted by Watch List News and is the property of of Watch List News. If you are accessing this report on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this report can be accessed at https://www.watchlistnews.com/geode-capital-management-llc-raises-stake-in-dynavax-technologies-corporation-dvax/1534432.html.

A number of research firms recently commented on DVAX. Cowen and Company reaffirmed an “outperform” rating and issued a $30.00 price target on shares of Dynavax Technologies Corporation in a report on Thursday, August 10th. William Blair reaffirmed an “outperform” rating and issued a $30.00 price target on shares of Dynavax Technologies Corporation in a report on Wednesday, August 9th. Zacks Investment Research raised shares of Dynavax Technologies Corporation from a “sell” rating to a “hold” rating in a report on Friday, August 4th. BidaskClub cut shares of Dynavax Technologies Corporation from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Finally, J P Morgan Chase & Co raised shares of Dynavax Technologies Corporation from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $6.00 to $27.00 in a report on Monday, July 31st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. Dynavax Technologies Corporation presently has an average rating of “Hold” and an average target price of $23.34.

About Dynavax Technologies Corporation

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Institutional Ownership by Quarter for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.